Evidence map›Paper›PMID 34210148›Full record

ReviewTissue engineering. Part B, Reviews2022

Highlights on Advancing Frontiers in Tissue Engineering.

Nureddin Ashammakhi, Amin GhavamiNejad, Rumeysa Tutar, Annabelle Fricker, Ipsita Roy, Xanthippi Chatzistavrou, Ehsanul Hoque Apu, Kim-Lien Nguyen, Taby Ahsan, Ippokratis Pountos and 1 more

Abstract readReview
In one paragraph

Review in Tissue engineering. Part B, Reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. 3D Hybrid Bioprinting for Complex Multi-Tissue Engineering.bioRxiv : the preprint server for biology · 2025
    Article
  13. Review
  14. 3D Printing for Neural Repair: Bridging the Gap in Regenerative Medicine.Advanced materials (Deerfield Beach, Fla.) · 2025
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nureddin AshammakhiDepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA.ORCID 0000-0003-0181-6055
Amin GhavamiNejadAdvanced Pharmaceutics and Drug Delivery Laboratory, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.ORCID 0000-0002-0712-5653
Rumeysa TutarDepartment of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Annabelle FrickerDepartment of Materials Science and Engineering, Faculty of Engineering, University of Sheffield, Sheffield, United Kingdom.
Ipsita RoyDepartment of Materials Science and Engineering, Faculty of Engineering, University of Sheffield, Sheffield, United Kingdom.
Xanthippi ChatzistavrouDepartment of Chemical Engineering and Material Science, College of Engineering, Michigan State University, East Lansing, Michigan, USA.
Ehsanul Hoque ApuDepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, California, USA.
Kim-Lien NguyenDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Taby AhsanRoosterBio, Inc., Frederick, Maryland, USA.
Ippokratis PountosAcademic Department of Trauma and Orthopaedics, University of Leeds, Leeds, United Kingdom.
Edward J CatersonDivision of Plastic Surgery, Department of Surgery, Nemours/Alfred I. du Pont Hospital for Children, Wilmington, Delaware, USA.

Funding

Ferumoxytol-Enhanced Cardiac MRI for Ischemic Heart DiseaseR01HL148182 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NGUYEN, KIM-LIEN T · 2020 to 2024
$3.8M
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool.UG3TR003148 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ASHAMMAKHI, NUREDDIN, KHADEMHOSSEINI, ALI · 2019 to 2021
$2.1M
CSRD VA I01 CX001901NCATS NIH HHS UG3 TR003148NHLBI NIH HHS R01 HL148182
6 · The paper itself

Abstract

The field of tissue engineering continues to advance, sometimes in exponential leaps forward, but also sometimes at a rate that does not fulfill the promise that the field imagined a few decades ago. This review is in part a catalog of success in an effort to inform the process of innovation. Tissue engineering has recruited new technologies and developed new methods for engineering tissue constructs that can be used to mitigate or model disease states for study. Key to this antecedent statement is that the scientific effort must be anchored in the needs of a disease state and be working toward a functional product in regenerative medicine. It is this focus on the wildly important ideas coupled with partnered research efforts within both academia and industry that have shown most translational potential. The field continues to thrive and among the most important recent developments are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies that warrant special attention. Developments in the aforementioned areas as well as future directions are highlighted in this article. Although several early efforts have not come to fruition, there are good examples of commercial profitability that merit continued investment in tissue engineering. Impact statement Tissue engineering led to the development of new methods for regenerative medicine and disease models. Among the most important recent developments in tissue engineering are the use of three-dimensional bioprinting, organ-on-a-chip, and induced pluripotent stem cell technologies. These technologies and an understanding of them will have impact on the success of tissue engineering and its translation to regenerative medicine. Continued investment in tissue engineering will yield products and therapeutics, with both commercial importance and simultaneous disease mitigation.

Indexed as

BioprintingTissue EngineeringHumansPrinting, Three-DimensionalRegenerative Medicine3D bioprintingorgan-on-a-chipregenerative medicinestem cellstissue engineering

Identifiers

PMID34210148
PMCPMC9242713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.